المؤلفون: Lazarus R; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK. Electronic address: rajeka.lazarus@uhbw.nhs.uk., Baos S; Bristol Trials Centre, University of Bristol, Bristol, UK., Cappel-Porter H; Bristol Trials Centre, University of Bristol, Bristol, UK., Carson-Stevens A; Division of Population Medicine, School of Medicine, Cardiff University, Cardiff, UK., Clout M; Bristol Trials Centre, University of Bristol, Bristol, UK., Culliford L; Bristol Trials Centre, University of Bristol, Bristol, UK., Emmett SR; Royal United Hospitals NHS Foundation Trust, Bath, UK., Garstang J; Knowle House Surgery, Plymouth, UK., Gbadamoshi L; Royal United Hospitals NHS Foundation Trust, Bath, UK., Hallis B; Porton Down, Public Health England, Salisbury, UK., Harris RA; Bristol Trials Centre, University of Bristol, Bristol, UK., Hutton D; Bristol Trials Centre, University of Bristol, Bristol, UK., Jacobsen N; Newquay Health Centre, North Coast Medical, Newquay, UK., Joyce K; Bristol Trials Centre, University of Bristol, Bristol, UK., Kaminski R; Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK., Libri V; University College Hospitals NHS Foundation Trust, London, UK., Middleditch A; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., McCullagh L; University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK., Moran E; North Bristol NHS Trust, Bristol, UK., Phillipson A; Rotherham Doncaster and South Humber NHS Foundation Trust, Doncaster, UK., Price E; Great Western Hospitals NHS Foundation Trust, Swindon, UK., Ryan J; The Alverton Practice, Atlantic Medical, Penzance, UK., Thirard R; Bristol Trials Centre, University of Bristol, Bristol, UK., Todd R; Bristol Trials Centre, University of Bristol, Bristol, UK., Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Oxford NIHR-Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Tucker D; Royal Cornwall Hospitals NHS Trust, Truro, UK., Williams RL; North Bristol NHS Trust, Bristol, UK., Nguyen-Van-Tam JS; Division of Epidemiology and Public Health, University of Nottingham School of Medicine, Nottingham, UK., Finn A; Bristol Vaccine Centre, Bristol Medical School, Bristol Population Health Sciences and School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK., Rogers CA; Bristol Trials Centre, University of Bristol, Bristol, UK.

مؤلفون مشاركون: ComfluCOV Trial Group

المصدر: Lancet (London, England) [Lancet] 2021 Dec 18; Vol. 398 (10318), pp. 2277-2287. Date of Electronic Publication: 2021 Nov 11.

نوع المنشور: Clinical Trial, Phase IV; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: BNT162 Vaccine/*administration & dosage , COVID-19/*prevention & control , ChAdOx1 nCoV-19/*administration & dosage , Influenza Vaccines/*administration & dosage , Influenza, Human/*prevention & control, Adult ; Aged ; BNT162 Vaccine/immunology ; COVID-19/immunology ; ChAdOx1 nCoV-19/immunology ; Female ; Humans ; Influenza Vaccines/immunology ; Influenza, Human/immunology ; Male ; Middle Aged ; SARS-CoV-2 ; United Kingdom ; Vaccines, Inactivated